Regional nodal management in the light of the AMAROS trial

The last decade witnessed the gradual adoption of sentinel lymph node biopsy (SLNB) to stage the axilla of breast cancer (BC) patients presenting with clinically negative lymph nodes; aiming to minimize the complications of the formal (gold standard) axillary lymph node dissection (ALND). Although abandoning ALND in pathologically negative sentinel node (SN) became the current standard of care, a similar consensus remains lacking in patients with positive SN.